Cargando…
Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
OBJECTIVE: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. METHODS: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Tr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757991/ https://www.ncbi.nlm.nih.gov/pubmed/29379273 http://dx.doi.org/10.2147/PPA.S152870 |
_version_ | 1783290926993506304 |
---|---|
author | Bridges, John FP Beusterien, Kathleen Heres, Stephan Such, Pedro Sánchez-Covisa, Joaquín Nylander, Anna-Greta Chan, Elcie de Jong-Laird, Anne |
author_facet | Bridges, John FP Beusterien, Kathleen Heres, Stephan Such, Pedro Sánchez-Covisa, Joaquín Nylander, Anna-Greta Chan, Elcie de Jong-Laird, Anne |
author_sort | Bridges, John FP |
collection | PubMed |
description | OBJECTIVE: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. METHODS: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. RESULTS: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). CONCLUSIONS: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement. |
format | Online Article Text |
id | pubmed-5757991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57579912018-01-29 Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling Bridges, John FP Beusterien, Kathleen Heres, Stephan Such, Pedro Sánchez-Covisa, Joaquín Nylander, Anna-Greta Chan, Elcie de Jong-Laird, Anne Patient Prefer Adherence Original Research OBJECTIVE: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. METHODS: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. RESULTS: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). CONCLUSIONS: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement. Dove Medical Press 2018-01-04 /pmc/articles/PMC5757991/ /pubmed/29379273 http://dx.doi.org/10.2147/PPA.S152870 Text en © 2018 Bridges et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed |
spellingShingle | Original Research Bridges, John FP Beusterien, Kathleen Heres, Stephan Such, Pedro Sánchez-Covisa, Joaquín Nylander, Anna-Greta Chan, Elcie de Jong-Laird, Anne Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
title | Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
title_full | Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
title_fullStr | Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
title_full_unstemmed | Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
title_short | Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
title_sort | quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757991/ https://www.ncbi.nlm.nih.gov/pubmed/29379273 http://dx.doi.org/10.2147/PPA.S152870 |
work_keys_str_mv | AT bridgesjohnfp quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT beusterienkathleen quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT heresstephan quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT suchpedro quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT sanchezcovisajoaquin quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT nylanderannagreta quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT chanelcie quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling AT dejonglairdanne quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling |